Group 1 - Huajian Medical (01931) saw its stock price increase by nearly 13%, with a cumulative rise of over 130% in the past two weeks, reaching 5.12 HKD per share and a trading volume of 9.56 million HKD [1] - The company announced a strategic cooperation framework agreement with BGI CoWin to establish an innovative drug intellectual property tokenization fund, which will invest in projects under the NewCo+RWA Web3 exchange ecosystem in Hong Kong, the US, or other overseas regions [1] - BGI CoWin, initiated by the biotechnology leader BGI Genomics (300676), has extensive domestic and international investment experience and project resources in the fields of innovative medicine and drugs [1] Group 2 - Huajian Medical's market capitalization surged from 3.6 billion HKD to nearly 8 billion HKD due to seven strategic actions taken in July, including a dual primary listing announcement in the US and the launch of a new brand logo [2] - The company is positioning itself as a "new species" in the capital market through a cross-industry combination of "stablecoins + medical RWA" [2] - Ongoing applications for stablecoin licenses in New York and Hong Kong, along with the upcoming Nasdaq listing, signify the company's strategic thrust into transforming traditional medical finance by turning innovative drug assets into on-chain "digital gold" [2]